CSF2 and melanoma: Another oncolytic adenovirus, ONCOS-102, that was engineered to express GM-CSF, in combination with pembrolizumab, showed promising results in melanoma mouse models and is currently undergoing a pilot study in advanced melanoma patients after anti-PD1 treatment [76] (NCT03003676).